Статья
ПРЯМЫЕ ОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ ПРИ ТРОМБОЗЕ ЛЕВОГО ПРЕДСЕРДИЯ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ
Приводятся клинические наблюдения пациентов с лизисом тромбов в ушке левого предсердия на фоне анти-коагулянтной терапии, обсуждается целесообразность проведения чреспищеводной эхокардиографии перед выполнением кардиоверсии или катетерной изоляции устьев легочных вен у больных с фибрилляцией предсердий.
1. Ferner M, Wachtlin D, Konrad T et al. Rationale and design of the RE-LATED AF-AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation // Clin Res Cardiol. 2016 Jan;105(1):29-36. doi: 10.1007/s00392-015-0883-7.
2. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS // European Heart Journal. 2016. 37, 2893-2962. DOI: 10.1093/eurheartj/ehx039
3. Ревишвили А.Ш., Бойцов С.А., Давтян К.В. и др. Клинические рекомендации по проведению электро-физиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. М. - 2017, 704 с.
4. Marsico F., Cecere M., Parente A. et al. Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal // J Thromb Thrombolysis. 2017; 43(2):139-148. doi: 10.1007/s11239-016-1421-9.
5. Reers S., Agdirlioglu T., Kellner M. et al. Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists // Eur J Med Res. 2016; 21;21(1):41.
6. Calkins H., Hindricks G., Cappato R., et al. 2017 HRS/ EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary // J Arrhythm. 2017; 33(5): 369-409. doi: 10.1016/j.joa.2017.08.001.
7. Nagarakanti R., Ezekowitz M.D., Oldgren J. et al. Dabi-gatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion // Circulation. 2011; 18; 123(2): 131-6. doi: 10.1161/CIRCULA-TIONAHA.110.977546.
8. Flaker G., Lopes R.D., Al-Khatib S.M. et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) // J Am Coll Cardiol. 2014; 25; 63(11): 1082-7. doi: 10.1016/j.jacc.2013.09.062.
9. Kawabata M., Goya M., Sasaki T. et al. Left Atrial Appendage Thrombi Formation in Japanese Non-Valvular Atrial Fibrillation Patients During Anticoagulation Therapy - Warfarin vs. Direct Oral Anticoagulants // Circ J. 2017 25; 81(5): 645-651. doi: 10.1253/circj.CJ-16-1089.
10. Anselmino M., Garberoglio L., Gili S. et al. Left atrial appendage thrombi relate to easily accessible clinical parameters in patients undergoing atrial fibrillation transcatheter ablation: A multicenter study // Int J Cardiol. 2017 15; 241: 218-222. doi: 10.1016/j.ijcard.2017.04.014.
11. Gunawardene M.A., Dickow J., Schaeffer B.N. et al. Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: An approach towards an individualized use of transesophageal echocardiography // J Cardiovasc Electrophysiol. 2017; 28(10): 1127-1136. doi: 10.1111/jce.13279.
12. Lip G.Y., Hammerstingl C., Marin F. et al. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF) // Am Heart J. 2015; 169(4): 464-71.e2. doi: 10.1016/ j.ahj.2014.12.020.
13. Ammollo C.T., Semeraro F., Incampo F. et al. Dabiga-tran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activat-able fibrinolysis inhibitor // J Thromb Haemost. 2010; 8(4): 790-8. doi: 10.1111/j.1538-7836.2010.03739.x.
14. Lip G.Y, Hammerstingl C., Marin F. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF) // Am Heart J. 2016; 178: 126-34. doi: 10.1016/j.ahj.2016.05.007.
15. Ezekowitz M.D., Pollack C.V, Sanders P. et al. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial // Am Heart J. 2016; 179: 59-68. doi: 10.1016/j.ahj.2016.06.008.
16. Kawano H., Kohno Y., Izumida S. et al. Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation // Intern Med. 2015; 54(6): 601-4. doi: 10.2169/internalmedicine.54.3003.
17. Miwa Y, Minamishima T., Sato T. et al. Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban // J Arrhythm. 2016; 32(3): 233-5. doi: 10.1016/j.joa.2016.01.009.
18. Szegedi N., Geller L., Tahin T. et al. Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy // Orv Hetil. 2016 24; 157(4): 154-6. doi: 10.1556/650.2016.30350.
19. Koyama T., Otsuka Y., Kawahara M. et al. A left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban // Clin Case Rep. 2017 31; 5(5): 711-713. doi: 10.1002/ccr3.933.
20. Lau Y.C., Xiong Q., Shantsila E. et al. Effects of nonvitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation // J Thromb Thrombolysis. 2016; 42(4): 535-44. doi: 10.1007/s11239-016-1399-3.